AAVivo, Inc. to Present Precision AAV Capsid Engineering (PACE) Platform for In Vivo CAR-T Therapy at BIOHK2025
Txylo.com/10321336
Trending...
- Governor Abbott Names Bernal Chair Of The Texas State Board Of Social Worker Examiners
- Umbrella Becomes First FinOps Platform to Support AWS Billing Transfer Onboarding
- Altruvest and Financial Executives International Canada Announce Strategic Partnership to Strengthen Nonprofit Boards Across Canada
HOUSTON, Sept. 8, 2025 /PRNewswire/ -- AAVivo, Inc., a pioneering biotechnology developing novel, precision targeted biotherapeutics to enable in vivo generation of CAR-T cells, today announced that Chief Technology Officer & Founder, Haifeng Chen, Ph.D., will present at BIOHK2025, the Hong Kong International Biotechnology Conference & Exhibition.
In a presentation titled, "PACE: A Breakthrough AAV Capsid Engineering Platform Enabling In Vivo CAR-T Therapy and Precision Gene Delivery," Dr. Chen will discuss AAVivo's PACE platform, which enables the transformation of non-targeted AAV vectors into precise and cell specific gene delivery vectors. PACE is a core component of AAVivo's IntelligentAAV (iAAV) platform, which is designed to allow rapid development of precision biotherapies that can be produced by a patient's body for potent, long-term disease control. PACE-modified AAV vectors therapies produced by the platform can deliver diverse payloads to specific tissues or cell types to either enhance immune cell function, redirect cells in situ to produce targeted therapies locally and persistently, or to kill malignant cells directly.
More on Txylo.com
About AAVivo, Inc.
AAVivo, Inc. is a biotechnology innovator advancing precision-targeted biotherapeutics through its proprietary iAAV-based platform. By harnessing a suite of patented technologies, AAVivo enables the in vivo generation of CAR-T cells, offering a transformative alternative to traditional CAR-T therapies. The company's cutting-edge platform includes:
Together, these innovations provide higher yields, enhanced potency without the need for lymphodepletion, and superior scalability, unlocking the potential of AAV vectors across diverse indications. AAVivo's development pipeline, which includes AVO-100, the company's lead product for B cell malignancies, as well as AVO-200 and AVO-300 for solid tumors, positions the company as a leader in the rapidly growing gene therapy market, offering investors a unique opportunity to support a scalable, high-impact biotech platform. AAVivo is headquartered in Houston, Texas. For more information, visit https://aavivo.com/.
More on Txylo.com
Contact
Tiberend Strategic Advisors, Inc.
Investor Relations
Jon Nugent
205-566-3026
[email protected]
Media Relations
Casey McDonald
646-577-8520
[email protected]
SOURCE AAVivo, Inc.
In a presentation titled, "PACE: A Breakthrough AAV Capsid Engineering Platform Enabling In Vivo CAR-T Therapy and Precision Gene Delivery," Dr. Chen will discuss AAVivo's PACE platform, which enables the transformation of non-targeted AAV vectors into precise and cell specific gene delivery vectors. PACE is a core component of AAVivo's IntelligentAAV (iAAV) platform, which is designed to allow rapid development of precision biotherapies that can be produced by a patient's body for potent, long-term disease control. PACE-modified AAV vectors therapies produced by the platform can deliver diverse payloads to specific tissues or cell types to either enhance immune cell function, redirect cells in situ to produce targeted therapies locally and persistently, or to kill malignant cells directly.
More on Txylo.com
- Sidow Sobrino, the One and Only World's No.1 Superstar®, Launches Dangerous Joy
- Texas: Governor Abbott Statement On Colmenero Nomination
- Texas: Governor Abbott Reappoints Brown As Presiding Judge Of The Eleventh Administrative Judicial Region
- Texas: Governor Abbott Activates State Emergency Response Resources Ahead Of Severe Storms
- MediMobile Announces Launch of Post-Acute Package to Support Multi-Facility Rounding Teams
Details are as follows: | |
Presentation: | PACE: A Breakthrough AAV Capsid Engineering Platform Enabling In Vivo CAR-T Therapy and Precision Gene Delivery |
Presenter: | Haifeng Chen, Ph.D. Chief Technology Officer & Founder, AAVivo, Inc. |
Date & Time: | September 10, 2025, 3:00 PM HKT |
About AAVivo, Inc.
AAVivo, Inc. is a biotechnology innovator advancing precision-targeted biotherapeutics through its proprietary iAAV-based platform. By harnessing a suite of patented technologies, AAVivo enables the in vivo generation of CAR-T cells, offering a transformative alternative to traditional CAR-T therapies. The company's cutting-edge platform includes:
- BAC-to-AAV Technology, enabling large-scale, cost-effective AAV manufacturing
- Precision AAV Capsid Engineering (PACE), delivering highly specific cell targeting for enhanced therapeutic outcomes
- Selective toxin packaging (SToP) platform with microRNA safety shield, ensuring safe delivery of potent therapeutic genes
Together, these innovations provide higher yields, enhanced potency without the need for lymphodepletion, and superior scalability, unlocking the potential of AAV vectors across diverse indications. AAVivo's development pipeline, which includes AVO-100, the company's lead product for B cell malignancies, as well as AVO-200 and AVO-300 for solid tumors, positions the company as a leader in the rapidly growing gene therapy market, offering investors a unique opportunity to support a scalable, high-impact biotech platform. AAVivo is headquartered in Houston, Texas. For more information, visit https://aavivo.com/.
More on Txylo.com
- Slotozilla Expands Bonus Portfolio and Affiliate Reach Following iGB Barcelona 2026
- Future Plans for the "Home For The Homeless" in Houston, TX #Investors Needed
- XMax Inc. (N A S D A Q) Accelerates AI Expansion With $4.8 Million Contracted Revenue, $30+ Million Enterprise Pipeline and Strategic SpaceX Exposure
- Lnk.Bio Becomes the First Link-in-Bio Service Fully Manageable from Inside ChatGPT
- Did Drake Just Find His Next Signee? Peoria Rapper Rhymi Gifts "ICEMANDRAKE" Domains, Drops Debut Album Same Day
Contact
Tiberend Strategic Advisors, Inc.
Investor Relations
Jon Nugent
205-566-3026
[email protected]
Media Relations
Casey McDonald
646-577-8520
[email protected]
SOURCE AAVivo, Inc.
Filed Under: Business
0 Comments
Latest on Txylo.com
- Connecticut Resident Develops Patent-Pending Concept Exploring a New Approach to GPS Navigation
- JP Events Azerbaijan to Host 2nd Women in Motorsport Event During the Azerbaijan Grand Prix Week
- Pura Vida Chiropractic Becomes San Antonio's Only Certified CMRT Bilingual Practice
- Texas Pecan Cakes Establishes Austin as the Source for Authentic Mail-Order Pecan Cakes Nationwide
- Resident Inspect Joins Property Meld Nexus Network with API Integration
- L2 Aviation Awarded IDIQ Contract by the U.S. Army for M1A2 Abrams Tank
- Texas: Governor Abbott, FEMA Review Council Present Key Emergency Management Reform Recommendations
- Author Johanna Sparrow Surpasses 150+ Published Books Across Emotional Healing and Children's Literature
- Website Redesign Houston: Texas Web Studios Modernizes Business Websites for Higher Conversions
- Sycor.Rental Named Among 2026 Best Microsoft Dynamics ERP Supply Chain Solutions
- Texas: Governor Abbott Adds Coastal Communities To Severe Weather Disaster Declaration
- Texas: Governor Abbott Highlights $30 Million Philanthropic Investment To Expand Career Training Programs At TSTC
- Teknismart Solutions Launches iParley Trust Infrastructure Platform for IT Hiring
- Texas: Governor Abbott Appoints Timmons As District Attorney Of The 31st Judicial District in Gray, Hemphill, Lipscomb, Roberts, And Wheeler Counties
- Platte Canyon Capital Acquires 252-Unit Apartment Community in San Antonio, TX
- Governor Abbott Announces Texas Semiconductor Innovation Fund Grant To Texas A&M University
- Veikkaus Appoints New CFO as Finland's Gambling Monopoly Braces for Breakup
- Arlington Teen Earns Aviation Scholarship, Turns Grit and Hustle into Flight Path for Success
- 'Dino Detectives' Pre-Teen Mystery Book Nominated for the 2026 Moonbeam Children's Book Awards
- Texas Advisory Services Partners with SECNORA Inc